Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Hydreight Technologies Inc ( (TSE:NURS) ).
Hydreight Technologies Inc. has launched a new direct-to-consumer genetic testing and personalized wellness solution via its VSDHOne platform. This service allows patients to access at-home DNA testing kits and receive personalized health plans, enhancing preventive care and patient retention. The initiative positions Hydreight to capitalize on the growing consumer genomics market, expected to surpass $50 billion by 2030, and supports the company’s strategic goals of expanding high-margin services and increasing customer lifetime value.
More about Hydreight Technologies Inc
Hydreight Technologies Inc. is a digital health platform that provides compliant mobile and telehealth services across all 50 U.S. states. The company focuses on delivering healthcare solutions directly to consumers, including personalized wellness and genetic testing services, through its VSDHOne platform.
Average Trading Volume: 80,415
Technical Sentiment Signal: Buy
Current Market Cap: C$40.09M
For a thorough assessment of NURS stock, go to TipRanks’ Stock Analysis page.